Immune responses in liver cancer following treatment
Liver cancers consist of primary cancers which originate in the liver and metastatic cancers which originate in anothersite and spread to the liver.Liver cancer is one of the most common causes of cancer morbidity and mortality in the world. The incidence of bothprimary and metastatic liver cancers is rising. Current treatment is often limited to palliation and at present surgery isthe only potentially curative treatment. Unfortunately most patients are not eligible for curative surgery due to advanceddisease and as a result prognosis remains extremely poor for most patients with liver cancer. Hence there is apressing need for more effective treatments.The treatment of incurable liver cancer includes radiofrequency ablation (burning of tumour using a small needle viathe skin) transarterial chemoembolization (injection of chemotherapy directly into the blood vessel feeding the tumourfollowed by the blockage of its blood supply) and pharmacological therapy (drug that blocks tumour growth).The effectiveness of the above treatments is usually the result of direct tumour killing. However evidence from animal and human studies have also suggested an added effect of therapy in activating the immune system to generate ananticancerimmune response against the cancer cells. Importantly this anticancerimmune response has beenshown to be related to improved prognosis. The exact mechanism for this enhanced anticancerimmune response ispoorly understood. Unfortunately this anticancerresponse is short lived resulting in eventual progression of tumourgrowth.Better understanding of the nature and mechanisms involved in the immune responses generated in patientsfollowing conventional treatment may allow us to develop therapeutic strategies to augment the immune system andenhance anticancerimmune responses and thereby increase efficacy of therapy in liver cancer.
|PI Name||Adams - DH|
|Sponsor||University of Birmingham|
|Proposed End Date||01/05/2016|
|Study Run through CRF?||No|
|Recruitment so far||0|